Key Takeaways
- Strong quarter, strategic pivot underway: Revenue grew 19.9% YoY to $360.2 mn, with a 90 bps QoQ margin improvement to 14.9%, while management laid out a multiyear shift toward platform-driven, outcome-based services.
- Order book hits a new high-water mark: A $150 mn+, 7-year deal in BFSI, the largest transformation deal ever signed, and a $50 mn+, 5-year deal in Software, Hi-Tech & Emerging anchored on the SASVA platform signal deal sizes are scaling.
- Healthcare & Life Sciences crosses the $100 mn threshold: The vertical grew 52.6% YoY, meaning every vertical now runs above a $100 mn quarterly rate, a diversification milestone.
- Margins improved despite furloughs, but the path to 200 bps more is undefined: Utilization at 87.4% and contractor rationalization drove the beat, yet management deferred specifics on the medium-term margin target, pointing to pricing, nonlinear revenue and SG&A levers still in progress.
- What to watch next quarter: Whether the buoyant mood on discretionary spending translates into pipeline and closures, the pace of margin expansion from the exit run rate, and any quantification of the SASVA-led platform transition.
Demand Environment
- Broad-based growth with a US tilt: North America led at 21.1% YoY, and all client buckets grew healthily, with the top 5 up 31.7% and the top 10 contribution rising to 40% of revenue from 39.3% a year ago.
- Furloughs hit as expected: The ~100 bps seasonal impact was in line with projections, concentrated in the US calendar-year client base where Q3 is the heavy renewal quarter.
- Discretionary spending: mood is up, evidence is not: Management described sentiment as buoyant but said nothing has yet shown up in pipeline or closures, and asked investors to wait another quarter or two for clarity.
- Budget timing creates a lag: If client budget decisions firm up in February, the effect on pipeline and bookings will take more time to materialize, making Q4 the earliest window for a signal.
Kalra: "It is not a race to the bottom where we have to necessarily develop all this IP, deliver more value and pass on everything. That is not the way we are looking at it and that's not the way our customers are looking at it."
Deal Wins & Order Book
Two landmark deals anchor the quarter, one in BFSI and one in Software, Hi-Tech & Emerging, both carrying multiyear tenures and platform-centric delivery models.
| Deal | Details |
|---|---|
| Leading American Financial Services company | $150 mn+, 7-year deal, the largest transformation deal signed to date, to modernize legacy systems. |
| UK-based PE-owned software company | $50 mn+, 5-year deal to transform R&D operations, with SASVA license and customization as the core tenet. |
| Global payment technology company | Selected to revamp Enterprise Gateway Services. |
| Large US-based insurer | Selected to enhance automation of insurance and claims processes. |
| Global healthcare leader | Selected to modernize a platform focused on patient care and pharmacy, a new relationship in the UK geography. |
| Global specialty injectables leader | Sole-sourced deal to replace a legacy Contract Management System. |
| ITSM, observability and database performance provider | Selected as engineering partner to alleviate geopolitical business risks and globalize the talent pool. |
- Revenue conversion is a blend: Management explained that quarterly revenue growth draws on both current ACV conversion and TCVs built over several years, and that multiyear deals may not show renewals on the ACV side, making single-quarter ACV growth an incomplete signal.
- No backlog disclosure coming: Management stated plainly, "We don't announce backlog. We don't intend announcing backlog in the shorter run."
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| Healthcare & Life Sciences | ▲ Strong growth | 52.6% YoY; crossed $100 mn quarterly run rate, meaning all verticals now above that threshold. |
| BFSI | ▲ Strong growth | 22.0% YoY; anchored by the landmark $150 mn+ transformation deal and multiple insurance and payments wins. |
| Software, Hi-Tech & Emerging | ▬ Modest growth | 3.2% YoY; the $50 mn+ SASVA-anchored deal and engineering partnership wins signal platform-led momentum. |
AI, Platforms & the Strategic Pivot
The SASVA, iAURA and Gen AI Hub stack
- SASVA: The latest release integrates autonomous AI agents that can dynamically interact with multiple data sources, tools and platforms to automate entire workflows, from GitHub issue identification to pull request preparation.
- iAURA: Now powered by Agentic AI with improved personalization, contextual intelligence and privacy safeguards, including human-in-the-loop capabilities for business workflows.
- Gen AI Hub: New features enable creation and deployment of Agentic AI workflows, with integration into AutoGen, CrewAI and Langflow, targeting use cases in precision oncology, loan underwriting, credit assessment and clinical research.
- Arrka integration: AI governance and data privacy capabilities are being embedded across SASVA, iAURA and Gen AI Hub, and across industry verticals and service lines.
- Starfish integration: Building an integrated AI platform for contact centre modernization, with integrations to NICE, Five9, Amazon Connect and Google Contact Centre AI; management sees good traction and expects to share wins in coming quarters.
IP and patents
- 20+ patents filed across core AI, agentic AI, personalized AI, repository-level AI and productivity measurement, a signal the company is building defensible IP around its platform thesis.
The strategic pivot
- Platform-driven, outcome-based: Management's stated endeavor over the next several quarters and years is to transition increasingly toward platform-driven services and shift the business model to outcome-based engagements, leveraging proprietary IP and IP built with hyperscalers and ecosystem partners.
- The pyramid will fade: The CEO said the traditional delivery pyramid concept will fade over the next several quarters and years as the model shifts toward outcome-driven work, but cautioned this is a multiyear journey, not a near-term event.
- Decoupling from headcount-led growth is acknowledged as a multi-quarter, multiyear journey requiring sustained investment.
Kalra: "The pyramid etc. is going to change over a period of time, not necessarily next quarter, but over the next several quarters and years, you will see the pyramid concept fading away."
Margins
| Margin walk (QoQ) | Impact |
|---|---|
| Furloughs | –60 bps |
| Lower earnout credit vs prior quarter (₹15.22 cr reversal) | –100 bps |
| Utilization improvement (84.8% → 87.4%) + contractor cost rationalization + other operational initiatives | +140 bps |
| Strong dollar cross-currency | +50 bps |
| Lower resell revenue + improved pricing | +40 bps |
| Lower ESOP costs | +20 bps |
| Net change → 14.9% | +90 bps |
- Utilization is above the comfort band: At 87%+, utilization sits above the stated 83-85% comfortable range; management is comfortable sustaining higher levels in the short run but this lever is largely exhausted.
- The 200-300 bps medium-term aspiration remains an aspiration: Management pointed to pricing work with multiple customers (COLA clauses, change requests), nonlinear revenue as AI levers are utilized, SG&A optimization (where Persistent is higher than peers), and growth itself as margin levers, but gave no specific timeline for reaching the target.
- Exit run rate as the bridge: The CEO framed the margin trajectory as "if we were to deliver 14.5% for the full year, that means an exit run rate at a different level. That exit run rate for the year becomes an entry run rate for the next year," implying sequential improvement is built into the base.
- Earnout reversal provision is expected to end by the close of FY25; Q4 may carry some residual amount but Q1 FY26 should have none.
Kalra: "If we were to deliver 14.5% for the full year, that means an exit run rate at a different level. That exit run rate for the year becomes an entry run rate for the next year."
People & Operating Model
- Attrition ticked up but is manageable: TTM attrition at 12.6%, up from 11.9% a year ago, described as within the acceptable range.
- Headcount and pyramid: Management declined to give specific headcount addition plans or onsite-offshore ratio targets, instead framing the discussion around a two-tiered economy and a multiyear shift away from the pyramid model toward outcome-driven delivery.
- Annual planning concluded: The Huddle exercise brought together over 350 senior global leaders in Pune roughly two weeks before the call; the strategic roadmap includes categorizing three core verticals into sub-verticals with focused scale plans, doubling down on the top 100 customers, expanding alternate channels including private equity and sourcing advisors, and enhancing focus on global capability centers.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue aspiration | $2 bn annual revenue | By end of FY27 |
| Revenue aspiration | $5 bn in revenue | By FY31 |
| ETR guidance | 23%–23.5% for the full year | FY25 |
| Earnout reversal provision | Expected to end; Q4 may carry residual, Q1 FY26 none | By end of FY25 |
| Margin improvement aspiration | 200–300 bps improvement | Medium term, no date given |
| Europe revenue mix | Grow from 8–9% to 12–15% | No date given |
| Platform-driven, outcome-based transition | Shift business model toward platform-driven services and outcome-based engagements | Over next several quarters and years |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | US$360.2 million, +19.9% YoY and +4.3% QoQ |
| Revenue (₹) | ₹3,062.28 crore, +22.6% YoY and +5.7% QoQ |
| Constant currency revenue growth | 4.6% QoQ |
| EBIT margin | 14.9%, +90 bps QoQ and +35 bps YoY |
| EBIT (₹) | ₹455.73 crore, +25.5% YoY and +12.2% QoQ |
| Profit after tax margin | 12.2% |
| Profit after tax (₹) | ₹372.99 crore, +30.4% YoY |
| Earnings per share | ₹24.30, +28.4% YoY (adjusted for stock split) |
| Effective tax rate | 22.6%, vs 25.2% in Q2 FY25; full-year expected 23%–23.5% |
| Total Contract Value (TCV) bookings | US$594.1 million, with new bookings TCV of US$333.6 million |
| Annual Contract Value (ACV) bookings | US$428.3 million, with new bookings ACV of US$195.6 million |
| ACV growth (new business) | ~7% YoY (per an analyst's math) |
| Total ACV growth | ~9% YoY (per an analyst's math) |
| Healthcare & Life Sciences revenue growth | 52.6% YoY; crossed US$100 million quarterly run rate |
| Banking & Financial Services revenue growth | 22.0% YoY |
| Software, Hi-Tech & Emerging verticals revenue growth | 3.2% YoY |
| North America revenue growth | 21.1% YoY in USD terms |
| Europe revenue growth | 10.3% YoY in USD terms |
| India revenue growth | 12.1% YoY in USD terms |
| Rest of world revenue growth | 66.5% YoY in USD terms, on a low base |
| Top 10 customer revenue contribution | 40%, vs 39.3% in Q3 FY24 |
| Top 5 customer revenue growth | 31.7% YoY |
| Customers >US$1 million (trailing 12 months) | 189, vs 176 in Q3 FY24 |
| Utilization | 87.4%, up from 84.8% in Q2 FY25 |
| Total headcount | 23,941, +605 YoY |
| Voluntary attrition (trailing 12 months) | 12.6%, vs 11.9% in Q3 FY24 |
| Furlough impact on revenue | ~100 bps |
| Furlough impact on EBIT margin | 60 bps headwind |
| Earnout credit reversal | ₹15.22 crore, 100 bps headwind to EBIT margin QoQ |
| Cross-currency tailwind | 50 bps |
| Billed DSO | 64 days, improved 4 days QoQ |
| Unbilled DSO | 22 days, improved 2 days QoQ |
| OCF to PAT ratio | 84.4%, vs revised 80.7% in Q2 FY25 |
| Return on capital employed (ex-cash) | 38.1%, vs 35.8% in Q3 FY24 |
| Interim dividend | ₹20 per share (face value ₹5) |
| Forward contracts outstanding | US$300 million at average rate of ₹85.30 |
| Large deal win (BFSI) | 7-year, US$150 million+, largest transformation deal signed |
| Large deal win (Software, Hi-Tech) | 5-year, US$50 million+ |